Capricor rises after FDA asks for more data but no new trials for Duchenne therapy

Capricor Therapeutics

20/01/2026 14:29

** Shares of drugmaker Capricor Therapeutics CAPR.O rise 6.4% to $25.90 premarket

** Co says FDA has asked for additional documents to support its review of deramiocel, an experimental treatment for Duchenne muscular dystrophy, a muscle‑wasting disease

** Co says it plans to submit the full late‑stage trial report in February to address FDA's questions

** FDA did not request new trials or more patients, per co

** Co's deramiocel aims to help preserve muscle and heart function

** Late-stage trial showed improvements in strength and heart health - CAPR

** As of last close, stock up ~109% over the past year

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))